Margit M. Janát-Amsbury
Halia Therapeutics, a Salt Lake City-based clinical-stage biopharmaceutical company, has appointed Dr. Margit M. Janát-Amsbury as chief medical officer. She is an experienced leader of cross-functional early development teams in oncology and has more than 20 years of experience in academic and industry settings. Janát-Amsbury most recently served as an executive medical director in early oncology development at Amgen and was also the product team lead for Amgen’s prostate portfolio. Before joining Amgen, she oversaw the development of multiple small molecules at Tolero Pharmaceuticals, which Sumitomo Dainippon Pharma acquired in 2017. Janát-Amsbury has held faculty appointments with the Division of Gynecologic Oncology, the Department of Pharmaceutics and Pharmaceutical Chemistry and the Department of Bioengineering at the University of Utah, where she also served as co-director of the Center for Nanomedicine.
